KEK Nr.	Insel Nr.	Medikamente / Medicament / Médicament / Intervention
24/02'	**686**	Essex Studie P02370/ P02370 PEG-Intron™ Plus REBETOL® for the Treatment of Subjects With Chronic Hepatitis C Who Failed to Respond to Previous Combination Therapy (Any a Interferon Treatment in Combination with Ribavirin)
25/02'	**686**	Essex Studie P02569/ Peg-Intron as maintenance therapy vs an untreated control group in adult subjects with compensated cirrhosis (Metavir F4), secondary to chronic hepatitis C, who have failed to respond to therapy with any alpha interferon plus ribavirin
23/02'	**686**	Essex Studie P02570/ Peg-Intron maintenance therapy vs an untreated control group for prevention of fibrosis in adult subjects with chronic hepatitis C with hepatic fibrosis (metavir fibrosis score of F2 or F3) who failed therapy with Peg-Intron plus Rebetol (in protocol P03470)
22/04'	**915**	Wyeth 0468h1-313-euA randomized open-label comparative evaluation of conversion from Calcineurin inhibitor (CI) treatment to Sirolimus (SRL) treatment versus continued CI treatment in liver allograft recipients undergoing maintenance therapy
36/04	**Ø**	Prospective randomized controlled multicenter trial comparing transarterial chemoembolization (TACE) versus TACE plus radio frequency thermoablation for the treatment of HCC in patients on the waiting list for liver transplantation
200/06	**1402**	Novartis Telbivudine, CLDT600A2406 A randomized, open-label, controlled, multi-center two-year study comparing efficacy and safety of telbivudine (LDT600) 600 mg PO in combination with peg alpha-2a sq 180 µg with peg alpha-2a monotherapy, and with telbivudine monotherapy in treatment naïve patients with HBeAg-positive CHB
219/06	**686**	Essex Protease Inhibitor P03523A Safety and Efficacy Study of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1
229/06	**1469**	SASL 25, S-TACE-Studie BayerTransArterial ChemoEmbolisation mit Doxorubicin in comb. With systemic admin of sorafenib for pat with hepatocellular carcinoma
16/07	**Ø**	Novartis Certican CRAD001HDE10 (PROTECT)“A twelve-month, multicenter, randomised, open-label study of safety, tolerability and efficacy of Certican-based regimen versus calcineurin inhibitor-based regimen in de novo liver transplant recipients”
091/07'	**Ø**	SASL 24 Roche ML21071 (Ribavirinspiegel)Peg-IFN/RBV +/- EPO, Prospektive, offene, randomisierte, kontrollierte Therapiestudie zur Wirksamkeit und Verträglichkeit einer Ther. mit PegInterferon-alfa2a + serumspiegeladaptierter Ribavirindosis vs. PegInterferon- alfa2a + gewichtsadaptierter Ribavirindosis bei Pat. mit nicht vorbehandelter chronischer Hepatitis C

KEK Nr.	Insel Nr.	Medikamente / Medicament / Médicament / Intervention
212/07	**Ø**	Essex Protease Inhib Follow-up (P05063)Long-Term Follow-Up of Subjects in a Phase 2 or 3 Clinical Trial in which SCH503034 was Administered for the Treatment of Chronic Hepatitis C
222/07'	**Ø**	Sanofi Aventis STRONGEFC10143 Rimonabant (SR 141716) A double-blind, randomized, placbo-controlled, parallel group study of rimonabant 20 mg daily for the treatment of non-diabetic patients with nonalcoholic steatohepatitis (NASH)
223/07'	**Ø**	Sanofi Aventis STRONG 2EFC10144 - Rimonabant (SR141716) A double-blind, randomized, placebo-controlled, parallel group study of rimonabant 20 mg daily for the treatment of type 2 diabetic patients with nonalcoholic steatohepatitis (NASH)
023/08'	**1767**	SASL 32: Plasma Proteomics after Transarterial Chemo-Embolisation to identify Novel Biomarkers in Patients with HCC (nicht- invasive Biomarker für HCCProspektive Daten und Samples Studie (samples for und nach TACE
118/08'	**1691**	Bayer STORM “A Phase III randomized, double-blind, placebo-controlled study of sorafenib as adjuvant treatment for hepatocellular carcinoma after surgical resection or local ablation. (STORM)
194/08	**1638**	BI 1220.5 Antiviral effect, safety and pharmacokinetics of 1 daily BI201335 NA in hep C genotype 1 infected treatment-nnaiive patients for 24 weeks
212/08'	**Ø**	Johnson&Johnson TibotecTA randomized, double-blind, placebo-controlled, Phase III trial of 2 regimens of telaprevir (with and without delayed start) combined with pegylated interferon alpha2a (pegasys) and ribavirin (copegus) in subjects with chronic genotype 1 hepatitis C infection who failed prior pegylated interferon + ribavirin treatment
050/09	**1683**	Novartis CNIM811 B2202 A randomized, adaptive-design dose finding study to assess the antiviral efficacy and safety of NIM811 administered in combination with Standard of Care (SOC) for 12 weeks in relapsed HCV-1 infected patients
131/09	**1823**	SASL 28 A randomized open label study evaluating the efficacy of continuous telbivudine versus lamivudine in patients with HBeAg- negative Chronic Hepatitis B who had previously achieved an undetectable viral load during 24 weeks of telbivudine therapy
180/09	**1780**	Protokoll IKPV100Detektion von Schwefelwasserstoff als Intermediärprodukt beim Stoffwechsel von Acetylcystein und Carbozystein in humanen Proben

KEK Nr.	Insel Nr.	Medikamente / Medicament / Médicament / Intervention
202/09	1765	SASL 30, SAKK 77/09, Everolimus+TACE+DoxorubicinA phase I open label/Phase II randomized, double-blind, multicenter study investigating the combination of RAD001 and transArterial ChemoEmbolisation (TACE) with doxorubicin in patients with hepatocellular carcinoma eligible for TACE
252/09	1825	Astellas ASTER A proof-of-principle Study of oral Treatment with a novel PDE4 inhibitor ASP9831
262/09	Ø	SASL 27 EurowilsonWilson Disease: Creating a European clinical database and planning randomized clinical trials
033/10	1874	BI 1241.21, Swissmedic 2010DR2084Sicherheit, antivirale Wirksamkeit und Pharmakokinetik von BI207127 in Kombination mit BI 201335 und mit Ribavirin während 4 und mit oder oder Ribavirin während 24-48 Wo bei Pat mit chronischer HCV Genotyp1
44/10	1857	SASL 31 Prospective evaluation of the performance of the HepIFN-Test for the prediction of response to therapy with pegylated Interferon-a and ribavirin in patients with chronic hepatitis C
65/10	1898	Kohortenstudie von Patienten mit HCC, ohne Sponsor, keine Medi, kein Blut, nur Fragebögen
100/10	1893	Roche ML25224 (Retro) CMV in OLTRetrospective Review of Valganciclovir Efficacy in Preventing CMV Disease in D+/R-Liver Transplant Recipients a Non Interventional Program / Protocol No. ML 25224
150/10	1988	Parexel, REACH, IMCL-CP12-0919 Imclone, Lilly, A Multicenter, Randomized, Double-blind, Phase 3 Study of Ramucirumab (IMVC- 1121B) Drug Product and Best Supportive Care (BSC) versus Placebo and BSC as Second-line Treatment in Patients With Hepatocellular Carcinoma Following First-line Theapy With sorafenib
181/10	Ø	Canonic, CLIF Acute-on-Chronic Liver Failure in Cirrhosis (CANONIC) Core Study
232/10	1995	MTXH 07 NASH Prospektive, multizentrische Sammlung von Plasma- und Urinproben zur Abgrenzung von histologisch bestätigter, nicht-alkoholinduzierter Steatohepatitis und nicht-alkoholinduzierter Fettleber

KEK Nr.	Insel Nr.	Medikamente / Medicament / Médicament / Intervention
36/11'	**2053**	BI 1220.30 Eine randomisierte, doppelblinde und placebokontrollierte Phase III Studie mit einmal täglich 120 mg BI 201335 für 12 oder 24 Wochen, oder einmal täglich 240 mg BI 201335 für 12 Wochen in Kombination mit pegyliertem Interferon-α und Ribavirin bei nicht vorbehandelten Patienten mit chronischer Hepatitis C Infektion vom Genotyp 1
062/11	**Ø**	GenomALC (NIH)Genetic risk factors for alcoholic liver cirrhosis - genome wide case control study (genomALC Consortium)
none	**Ø**	SASL 19: TACE vs TACE + RFA on the waiting list Phase I7IIProspective randomized controlled multicenter trial comparing transarterial chemoembolization (TACE) versus TACE plus radio frequency thermoablation for the treatment of hepatocellular carcinomas in patients on the waiting list for liver transplantation
77/11	**2067**	Janssen-Cilag Protokoll EDMS-ERI-16341926:1.0; EudraCT Nr.: 2010-023669-23, Fokus: LeitEK SG; lokale EK's: BE, BB, ZH, VD, TI, GE, VX-950 HEP3002, VX-950 TelaprevirMulticenter, open-label, Early Access Program of Telaprevir in Combination with Peginterferon Alfa and Ribavirin in Genotype 1 Chronic Hepatitis C Subjects with Severe Fibrosis and Compensated Cirrhosis
104/11	**2095**	BI 1220.48 A phase III, open-label study of once daily BI 201335 240 mg for 24 weeks in combination with pegylated interferon-α (PegIFN) and ribavirin (RBV) in patients with genotype 1 chronic hepatitis C infection who failed a prior PegIFN / RBV treatment
105/11	**2096**	BI No 1220.7: A phase III, randomised, double-blind and placebo controlled study of once daily BI 201335, 240 mg for 12 or 24 weeks in combination with pegylated interferon-α and ribavirin in patients with genotype 1 chronic hepatitis C infection who failed a prior PegIFN/RBV treatment)
38/12	**Ø**	Attain (TMC435HPC3001) (Tibotec)A Phase III, randomized, double-blind trial to evaluate the efficacy, safety and tolerability of TMC435 vs. Telaprevir, both in combination with PegIFNalpha-2a and ribavirin, in chronic hepatitis C genotype-1 infected subjects who were null or partial responders to prior PegIFNalpha and ribavirin therapy
063/12	**2554**	Nashville2, Dr. Pierre Rimbaud enterome Une enquête transversale multicentrique, qui a pour objectif de valider la relation de la signature métagenomique avec ll stade évolutif de la stéatohépatite
87/12	**2215**	AI447-029 (Bristol-Myers Squibb) A Phase 3, Open-Label Study with Asunaprevir and Daclatasvir Plus Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegut) (P/R) (QUAD) for Subjects Who Are Null/Parial Responders to P/R with Chronic Hepatitis C Genotypes 1a, 1b and 4 Infection
87/12	**2215**	AI452-021 (Bristol-Myers Squibb)Evaluation of daclatasvir in combination with peginterferon lambda-1a and ribavirin or telaprevir in combination with peginterferon alfa-2a and RBV in patients with chronic hepatitis C GT1 who are treatment naive or prior relapsers to alfa/RBV therapy

KEK Nr.	Insel Nr.	Medikamente / Medicament / Médicament / Intervention
123/12	**2343**	Abbot M13-389 A Randomized, open-label, multicenter study to evaluate the safety and antiviral activity of the combination of ABT-450 with ritonavir (ABT-450/r), ABT-267, and ABT-333 with and without ribavirin in treatment-experienced subjects with genotype 1 chronic hepatitis C-virus (HCV) infection (PEARL-II)
124/12	**2241**	Abbott M13-101
219/12	**2327**	Abbott M11-646: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT 267 (ABT-450/r/ABT-267) and ABT-33 Co-administered with Ribavirin (RBV) in Treatment-Naive Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-I)
190/12	**Ø**	CT 5006 Rhudex (CATO) PBZ-Studie
23/13	**2357**	BI 1241.20: A Phase III, Randomised, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV Infection
56/13	**2422**	BAYER HCC 15982: Eine randomisierte, doppelblinde, placebokontrollierte, multizentrische Studie der Phase III zu Regorafenib bei Patienten mit hepatozellulärem Karzinom (HCC) nach Sorafenib (Resource)
106/13	**2404**	BAYER HCC 16553: Prospektive, multizentrische, einarmige, unkontrollierte, offene Phase II Studie mit Refametinib (BAY86-9766) bei Patienten mit RAS-mutiertem hepatozellulärem Karzinom (HCC)
107/13	**Ø**	BI 1241.30: Eine randomisierte, doppelblinde und placebokontrollierte Phase II Studie mit BI 207127 in Kombination mit Faldaprevir und Ribavirin in Patienten mit mittelschwerer Leberinsuffizienz (Child-Pugh B) und chronischer Hepatitis-C-Virus Infektion vom Genotyp 1b
208/13	**2488**	GS-US-337-0124: A phase 2, multicenter, open-label study to investigate the safety and efficacy of sofosbuvir/ledipasvir fixed-dose combination " ribavirin administered in subjects infected with chronic HCV who have advanced liver disease or are post-liver transplant
076/14	**Ø**	Genotypic and Phenotypic Characterisation of Albumin in Cirrhotic Patients

KEK Nr.	Insel Nr.	Medikamente / Medicament / Médicament / Intervention
090/14	**2569**	Investigation of the Endocannabinoid System in Hepatitis C Infection
none	**Ø**	Scotch: Zirrh. Pat mit Leberversage. Kortison ja oder nein auf IB
140/14	**2560**	Immunpathogenese Hepatitis B
141/14	**2566**	A metabolomic and lipidomic investigation in patients with viral hepatitis
072/14	**Ø**	AVB/13 (akute Varizenblutung)
192/14	**2584**	BAY 16728: A prospective, single-arm, multicenter-uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in combination with sorafenib as first line
071/15	**2756**	BAY 43-9006: OPTIMIS - „Outcomes of HCC patients treated with TACE followed or not followed by sorafenib and the influence of timing to initiate sorafenib“ (Ergebnisse von HCC-Patienten bei Behandlung mit TACE, entweder gefolgt von Sorafenib oder nicht gefolgt von Sorafenib, und den Einfluss des Zeitpunkts des Behandlungsbeginns mit Sorafenib)
none	**Ø**	BI 1241.45: A randomized, open label trial to evaluate the pharmacokinetic interactions between BI 207127/faldaprevir/ribavirin and darunavir/ritonavir or efavirenz in treatment of naive, partial response and prior relapse patients with genotype 1b chronic hepatitis C infection
-	**2046**	Role of dietary free fatty acids and pathological alterations of the miR21/PTEN pathway in an experimental model of hepatocellular carcinoma
265/15	**2934**	Abbvie M13-590: Endurance I, GNT3 Sof/Riba vs ABT493/ABT530 12 weeks, Genotype 1

KEK Nr.	Insel Nr.	Medikamente / Medicament / Médicament / Intervention
321/15	**2955**	Abbvie M13-594, Endurance 3: A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered with Daclatasvir in Adults with Chronic Hepatitis C Virus Genotype 3 Infection
362/16	**3031**	Swiss Hepatitis C Cohort Study: Does pregnancy protect against fibrosis or promote SVR in HCV infected women?
213/16	**Ø**	Tissue Factor in HCC
655/16	**3078**	GS-US-342-2104. A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination in Subjects with Chronic HCV Infection who have received a Liver Transplant
741/16	**3090**	Patients with Liver Cirrhosis: Analysis of the clinical and Radiological Characteristics of Large Spontaneous Portosystemic Shunts and Analysis of Muscle Mass depletion as a Predictor in Morbidity
1840/16	**3258**	Abbvie M15-942 Magellan. An open-label, multicenter study to evaluate the efficacy and safety of AT-493/ABT-530 in combination with Sofosbuvir and Ribavirin in chronic hepatitis C (HCV) infected subjects who have experienced virologic failure in AbbVie HCV clinical studies
1542/16	**3207**	GS-US-416-2124 (A Phase 2, double blind, randomized study evaluating the safety, tolerability and efficacy of GS-4997 in combination with prednisolon versus prednisolon alone in subjects with severe alcoholic hepatitis (AH)
0148/17	**3274**	Beurteilung des Hämophagozytose-Syndroms und der histologischen Hämophagozytose am Inselspital
1353/16	**Ø**	Quantitative analysis of speed of sound ultrasound images in patients with chronic liver disease
1959/16	**3293**	GS-US-402-1852 NASH: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Nonalcoholic Steatohepatitis (NASH)

KEK Nr.	Insel Nr.	Medikamente / Medicament / Médicament / Intervention
0362/16	**3031**	HCV Cohort: Gender Specific Outcome of HCV Infection in the Swiss HCV Cohort Pregnancy as Protective Factor for Advanced Fibrosis and Predictor of SVR
1738/16	**3319**	Hematite: Quality of Life Measurement Using Wrist Actigraphy in HCV Genotype 1 Infected, Treatment Naive Patients Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir Tablets and Dasabuvir Tablets (Viekirax/Exviera; 3D regimen)
075 /17	**3284**	SASL 36: The health burden of Primary Biliary Cirrhosis in Switzerland
570/17	**3494**	Novartis PDR001G2101 HCC: A phase Ib study of PDR001 in combination with Sorafenib in patients with untreated advanced hepatocellular carcinoma (HCC)
971/17	**3449**	NOVARTIS NASH CCLMB763X2201: A randomized, patient and investigator blinded, placebo-controlled, multicenter study to assess the safety, tolerability, pharmacokinetics and efficacy of LMB763 in patients with NASH
1056/17	**3387**	MK-3682-021 DAA Failure: A Phase 11, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-3682B (MK-5172 + MK- 3682 + MK-8408 Fixed Dose Combination (FDC)) in Subjects with Chronic HCV GT1 or GT3 Infection who have failed a Direct Acting Antiviral Regimen
110/17	**3307**	GS-US-337-4063 Safety and Efficacy of Ledipasvir/Sofosbuvir in patients with chronic HCV infection who are on dialysis for end stage renal disease
1582/17	**3527**	SMART-C: A phase IIIb, open-label, multicentre, international randomised controlled trial of simplified treatment monitoring for 8 weeks glecaprevir (300mg)/pibrentasvir (120mg) in chronic HCV treatment naïve patients without cirrhosis
0148/17	**3274**	Hemophagocytosis
1563/17	**3483**	Retrospective Study in the Use of the Alfapump and the Treatment of Malignant Ascites

KEK Nr.	Insel Nr.	Medikamente / Medicament / Médicament / Intervention
524/17	3339	Exalenz. Clinical Study of the BreathID® MCS System to train the algorithm for the ^{13}C-Methacetin Breath Test (MBT) in assessment of Portal Hypertension in Patients with Compensated Liver Cirrhosis. Protocol No. CSPH-EX-0414
1581/18	3796	APD334-010: An open-label, pilot, proof of concept study to evaluate the safety, tolerability, and efficacy of oral etrasimod (APD334) in patients with primary biliary cholangitis
120/13	2412	ARQ 197-A-U303 (METIV-HCC): A phase 3, randomized, double-blind study of Tivantinib (ARQ197) in subjects with MET diagnostic- high inoperable HCC treated with one prior systemic therapy
0550/17	3353	GS-US-384-1943 NASH and bridging cirrhosis. Stellar 3
1077/18	3955	NOVARTIS NASH CLJC242A2201J TANDEM: A randomized, double-blind, multicenter study to assess the safety,tolerability, and efficacy of a combination treatment of tropifexor (LJN452) and cenicriviroc (CVC) in adult patients with nonalcoholic steatohepatitis
038/14	2708	INFECIR-2: Albumin administration in the prevention of hepatorenal syndrome and death in patients with cirrhosis, bacterial infections other than spontaneous bacterial peritonitis and high risk of hospital mortality SCNTP880
2178/17	3604	Mythen: Hep C and microbiota (Abbvie): Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir plus Pibrentasvir in Patients with Chronic Hepatitis C Genotypes 1 to 6 (post-marketing).
1581/18	Ø	Arena APD 334 PBC. Estrasimod Sans Phase 2
104/11	2095	BI 1220.48
2129/16	3287	Inventiva NATIV IVA337 Phase 2b NASH study

KEK Nr.	Insel Nr.	Medikamente / Medicament / Médicament / Intervention
030/11	**2034**	NASH EU FLIP Cohort EU-FLIP Cohort of patients with non-alcoholic steatohepatitis
2129/16	**3287**	NATIVE: A randomized, double-blind, placebo-controlled, multicenter, dose-range, proof-of-concept, 24-week treatment study of IVA337 in adult subjects with nonalcoholic steatohepatitis (NASH)
1070/18	**3757**	Alfapump Nutrition: Untersuchung des Einflusses von Ernährungsfaktoren auf das Outcome von Patienten mit einer alfa (automated low-flow ascites) Pumpe
075/17	**3309**	HEPCASUS: Genome studies of hepatocellular carcinoma developed in hepatitis C patients with sustained virolgoical response
-	**Ø**	Biotest: A Retrospective Data Collection to Increase the Knowledgebase of Post-Transplant Treatment with the Human Hepatitis B Immunoglobulin Zutectra or Hepatect CP in Liver Transplanted Patients
2023/16	**3249**	Bern-Lugano HCV Study: Retrospective analysis of the outcomes of HCV infected individuals in the hospital setting in Switzerland
2063/17	**Ø**	Gilead AIDAA: Effect of HCV clearance by DAA on evolution of AIDS, or: DAA on evolution of AIDs (SASL42)
073/12	**Ø**	PMSR, Sequana Medical AG ALFApump-System Post-Market-Beobachtungsregister - Zur Unterstützung der folgenden Indikation: Automatische Entfernung überschüssiger Peritonealflüssigkeit in die Harnblase bei Patienten mit Zirrhose sowie mit persistenter und refraktärer Aszites, Code: 2011-AAR-004
501/17	**3303**	The added value of CAP in advanced chronic liver disease
291/17	**3337**	Predicting Acute-on-Chronic Liver Failure in Cirrhosis

KEK Nr.	Insel Nr.	Medikamente / Medicament / Médicament / Intervention
168/17	**3535**	OLT for refractory ascites
038/14	**2708**	INFECIR-2: Albumin administration in the prevention of hepatorenal syndrome and death in patients with cirrhosis, bacterial infections other than spontaneous bacterial peritonitis and high risk of hospital mortality SCNTP880
125/12	**2224**	HBV-Genomics: Human Genomics of Fulminant Hepatitis B Infection
213/13	**2492**	SASL 35: Swiss Liver Venous Thrombosis Study: A multicenter prospective observational cohort study
0010/16	**2959**	Quality Assessment in Hepatic Hemodynamic Procedures at Inselspital: Radiation Exposure, Iodine Contrast Use and Procedure Related Complications.
1581/18	**3796**	APD334-010: An open-label, pilot, proof of concept study to evaluate the safety, tolerability, and efficacy of oral etrasimod (APD334) in patients with primary biliary cholangitis
932/16	**3135**	T-cell response in DILI (Amendment to DILI)
001/16	**2959**	SARCOPENIA: Quality Assessment in hepatic hemodynamic procedures at Inselspital: Radiation exposure, iodine contrast use and procedure related complications
957/17	**3411**	Association between imaging biomarkers of body composition and prognosis in patients with advanced chronic liver disease and in patients with hepatocellular carcinoma (HCC) (Retrospective study with further use of health-related personal data)
246/00	**2985**	HCV Kohorte. SCCS - Schweizerische Hepatitis C Kohortenstudie mit Hepatitis C Virus Infizierten: Lack of Physical Activity as a Risk Factor for HCC in Patients with chronic Hepatitis C, Analyse von Blutproben gesammelt im Rahmen der SCCS-Kohortenstudie.

KEK Nr.	Insel Nr.	Medikamente / Medicament / Médicament / Intervention
235/12	2307	SASL-34 Treatment of non-alcoholic steatohepatitis (NASH) patients with vitamin D. A randomized, double blind, placebo-controlled multicentre phase II trial in patients with fatty liver disease.
1418/16	-	Conatus IDN-6556-14 A Multicenter, Randomized, Double-Blind, Placebo- Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension. (ENCORE-PH).